New hope for Tough-to-Treat blood cancer: experimental combo enters human testing
NCT ID NCT07355335
Summary
This early-stage study aims to find a safe dose and check side effects of combining two experimental drugs, ziftomenib and mezigdomide, for people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. It will enroll about 24 adolescents and adults with specific genetic types of AML. The main goal is to see how well patients tolerate the combination and determine the best dose for future research.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KMT2A-REARRANGED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.